SCHEMBL5632077

SCHEMBL5632077

CC(C)c1nc2c(c(Nc3ccc4c(c3)N(C)CCC4)n1)CCN(c1ncccc1C(F)(F)F)CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 19/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633586 0.90 TRPV1 (1.00) TRPV1
Hydrochloric Acid SCHEMBL5633912 0.89 TRPV1 (0.98) TRPV1
SCHEMBL5632423 0.88 TRPV1 (1.00) TRPV1
SCHEMBL5633700 0.88 TRPV1 (1.00) TRPV1
SCHEMBL4494408 0.87 TRPV1 (1.00) TRPV1
Hydrochloric Acid SCHEMBL5632921 0.87 TRPV1 (0.98) TRPV1
SCHEMBL4191281 0.86 TRPV1 (1.00) TRPV1
SCHEMBL4560240 0.86 TRPV1 (0.87) TRPV1
SCHEMBL4192688 0.85 TRPV1 (1.00) TRPV1
SCHEMBL5634295 0.85 TRPV1 (1.00) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738649-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2017-08-22 US claimed
US-20160318942-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 US claimed
US-20140135311-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2014-05-15 US claimed
US-20070225275-A1 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-27 US claimed
US-9738649-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2017-08-22 US disclosed
US-9738649-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2017-08-22 US disclosed
US-9738649-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2017-08-22 US disclosed
US-20160318942-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 US disclosed
US-20160318942-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 US disclosed
US-20160318942-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 US disclosed
US-9422293-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2016-08-23 US disclosed
US-9422293-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2016-08-23 US disclosed
EP-2024368-B1 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN JANSSEN PHARMACEUTICA NV (BE) 2014-04-30 EP disclosed
EP-2024368-B1 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN JANSSEN PHARMACEUTICA NV (BE) 2014-04-30 EP disclosed
US-8673895-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2014-03-18 US disclosed
US-8673895-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2014-03-18 US disclosed
US-8673895-B2 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA NV (BE) 2014-03-18 US disclosed
US-20070225275-A1 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-27 US disclosed
US-20070225275-A1 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-27 US disclosed
US-20070225275-A1 Tetrahydro-pyrimidoazepines as modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318942-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 TRPV1, TRPA1, TRPV2 TRPV1 1/4885
US-20140135311-A1 TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 TRPV1, TRPA1, TRPV2 TRPV1 1/4885
US-20070225275-A1 Tetrahydro-pyrimidoazepines as modulators of TRPV1 TRPV1, TRPA1, TRPV2 TRPV1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.